Located in Boston and the surrounding communities, Dana-Farber Cancer Institute brings together world renowned clinicians, innovative researchers and dedicated professionals, allies in the common mission of conquering cancer, HIV/AIDS and related diseases. Combining extremely talented people with the best technologies in a genuinely positive environment, we provide compassionate and comprehensive care to patients of all ages; we conduct research that advances treatment; we educate tomorrow's physician/researchers; we reach out to underserved members of our community; and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
The PROFILE program is a collaborative effort between Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Boston Children's Hospital to advance precision cancer medicine by implementing tumor genomic profiling for cancer patients at these hospitals. PROFILE employs state-of-the art genomics technology to generate a detailed report of genomic alterations in a CLIA-certified and real-time process to facilitate rapid clinical application. These cancer genomic profiles are being used to guide patient treatment and/or stratification for clinical trials of novel anticancer agents. Some technologies deployed in PROFILE are developed in the Center for Cancer Genome Discovery (CCGD) at Dana-Farber. This center facilitates genomic discoveries in cancer using novel technology platforms to assist researchers in both genome-wide and gene-focused efforts. Technologies are selected and developed with a view to research-oriented ventures, as well as translational medicine and clinical relevance.
Our clinical and research environments currently use state-of-the-art massively parallel sequencing assays of DNA and RNA from patient tumor samples. Data from these environments are used to advance research on both adult and pediatric cancers, improve our understanding of cancer biology, and advance the field of precision cancer medicine. This opportunity offers the chance to work at the forefront of translational cancer technologies and applications, in an informatics group that enables analyses in both arenas.
The primary responsibility of this role will lead the development and validation of multi-omic analytical methodologies for both cutting-edge research and clinical applications (such as development of analyses for liquid biopsies and structural variant detection). Working with scientific and clinical colleagues, the capabilities developed will be applied to precision cancer medicine efforts at our institutions. To make significant contributions to the research and clinical efforts described above, the candidate will have the ability to quickly arrive at innovative and effective solutions both as part of a team and independently.
Knowledge, Skills and Abilities Required
Bachelor’s degree required, MS or PhD preferred in Bioinformatics, computational biology, or computer science or equivalent experience and 6-9 years relevant experience with 2+ years’ experience.
Dana-Farber Cancer Institute is an equal opportunity employer and affirms the right of every qualified applicant to receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other groups as protected by law.